@article{FRANCOEUR2025, 
author = {ALEX A. FRANCOEUR and NATALIE AYOUB and DANIELLE GREENBERG and KRISHNANSU S. TEWARI},
title = {Drug discovery in advanced and recurrent endometrial cancer: Recent advances},
year = {2025},
journal = {Oncology Research},
volume = {33},
number = {7},
pages = {1511-1530},
keywords = {Advanced endometrial cancer, Recurrent endometrial cancer, Drug discovery, Tumor cancer genome atlas, Targeted therapy, Chemotherapy, immunotherapy},
url = {https://www.sciopen.com/article/10.32604/or.2025.061120},
doi = {10.32604/or.2025.061120},
abstract = {Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy.}
}